merck Reaffirms Commitment to Childhood Immunization Amidst Schedule Updates
January 9, 2026 01:45:51
Rahway, N.J. – Merck today reiterated its dedication to safeguarding children’s health thru robust immunization programs, following recent adjustments to the U.S. childhood immunization schedule by the Department of Health and Human Services (HHS).The company emphasized the critical role of vaccines in preventing serious infectious diseases and maintaining community health.
The Importance of Childhood vaccination
For decades, childhood vaccination has been a cornerstone of public health, dramatically reducing the incidence of diseases like measles, polio, and hepatitis B. merck highlights that these successes are built on a foundation of rigorous scientific research,continuous safety monitoring,and real-world evidence gathered from millions of children. Vaccines are developed and timed based on factors like waning maternal antibodies, disease exposure risks, immune system growth, and effective delivery methods.
As the HHS updates immunization recommendations, Merck stresses the importance of basing these changes on complete data and the expertise of professionals in vaccinology, pediatrics, infectious diseases, and epidemiology. International comparisons should be considered, but within the context of differing disease burdens, healthcare infrastructure, and population needs.
The company acknowledges the importance of shared clinical decision-making between healthcare providers and families, allowing for consideration of individual circumstances and risks. However, clear, evidence-based recommendations are essential for informed decisions and ensuring children receive reliable protection.
Merck’s Vaccine Portfolio and Safety Information
Merck offers a range of vaccines designed to protect children from preventable diseases.Key vaccines include:
M-M-R®II
This vaccine provides active immunization against measles, mumps, and rubella. the first dose is typically administered between 12 and 15 months of age, with a second dose given between 4 and 6 years of age.Learn more about M-M-R®II
Vital Safety Information: M-M-R®II is contraindicated in individuals with hypersensitivity to vaccine components, certain immune deficiencies, active febrile illness, untreated tuberculosis, or pregnancy. Caution is advised for those with a history of febrile seizures or egg allergies.
ProQuad®
ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella (chickenpox) in children aged 12 months through 12 years. Learn more about ProQuad®
Important Safety information: ProQuad shares contraindications with M-M-R®II and VARIVAX®,including hypersensitivity and immunodeficiency. Caution is advised regarding febrile seizures and family history of immunodeficiency.
VARIVAX®
VARIVAX provides active immunization against varicella. It is approved for individuals 12 months of age and older. Learn more about VARIVAX®
RECOMBIVAX HB®
RECOMBIVAX HB is a vaccine for the prevention of hepatitis B infection,approved for use in individuals of all ages,including specialized formulations for dialysis patients. Learn more about RECOMBIVAX HB®
Important Safety Information: RECOMBIVAX HB is contraindicated in individuals with severe allergic reactions to vaccine components.
VAXELIS®
VAXELIS is a combination vaccine offering protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. It is administered as a 3-dose series starting at 6 weeks of age. Learn more about VAXELIS®
Commitment to Safety and Innovation
Merck remains steadfast in its commitment to rigorous scientific standards, strong regulatory processes, and ongoing safety monitoring. The company will continue to collaborate with public health partners to support policies that protect children, strengthen communities, and advance the progress achieved through immunization.
Looking Ahead
Maintaining public confidence in vaccination programs is paramount. Merck believes that continued education, clear communication, and a commitment to scientific integrity are essential to ensuring high vaccination rates and protecting future generations from preventable diseases.
Disclaimer: This information is based on a press release from Merck & Co., Inc. and is intended for informational purposes only. Always consult with a healthcare professional for personalized medical advice.